Related Experiment Video

Updated: Feb 23, 2026

A Syngeneic Mouse Model of Metastatic Renal Cell Carcinoma for Quantitative and Longitudinal Assessment of Preclinical Therapies
06:38

A Syngeneic Mouse Model of Metastatic Renal Cell Carcinoma for Quantitative and Longitudinal Assessment of Preclinical Therapies

Published on: April 12, 2017

14.3K

Systemic treatment of renal cell cancer: A comprehensive review

Amparo Sánchez-Gastaldo1, Emmanuelle Kempf2, Aránzazu González Del Alba3

  • 1Medical Oncology Department, Hospital Universitario "Virgen del Rocio", Seville, Spain.

Cancer Treatment Reviews
|September 13, 2017
PubMed

Insights

Targeted therapies have improved outcomes for kidney cancer patients, specifically renal cell carcinoma (RCC). This review covers approved and emerging treatments, offering insights into current and future therapeutic strategies for RCC.

Area of Science:

  • Oncology
  • Nephrology
  • Pharmacology

Background:

  • Kidney cancer accounts for approximately 5% of all new cancer diagnoses.
  • Renal cell carcinoma (RCC) is the most common type of kidney cancer, originating from the renal epithelium.
  • RCC exhibits diverse histological and molecular subtypes.

Purpose of the Study:

  • To review currently approved targeted agents for renal cell carcinoma (RCC) treatment.
  • To discuss emerging molecules and future developments in RCC therapy.
  • To provide a comprehensive overview of the current landscape of targeted therapy in RCC.

Main Methods:

  • Review of approved targeted agents for RCC.
  • Discussion of preclinical and clinical development of agents.
  • Analysis of ongoing clinical trials for RCC treatments.

Main Results:

  • Several targeted agents have been developed based on molecular and cytogenetic understanding of RCC.
  • These agents have demonstrated improved treatment outcomes for patients with RCC.
  • The review presents a broad vision of current targeted therapy and future directions.

Conclusions:

  • Targeted therapy has significantly advanced RCC treatment.
  • Understanding molecular subtypes is crucial for developing effective therapies.
  • Ongoing research and development promise further improvements in RCC management.
Keywords:
AngiogenesisImmunotherapyMonoclonal antibodyRenal cell cancerTargeted therapyTyrosine-kinase inhibitormTOR inhibitor

More Related Videos

Modeling Spontaneous Metastatic Renal Cell Carcinoma mRCC in Mice Following Nephrectomy11:27

Modeling Spontaneous Metastatic Renal Cell Carcinoma mRCC in Mice Following Nephrectomy

Published on: April 29, 2014

17.2K
Treatment of Liver Metastases Using an Internal Target Volume Method for Stereotactic Body Radiotherapy08:54

Treatment of Liver Metastases Using an Internal Target Volume Method for Stereotactic Body Radiotherapy

Published on: May 8, 2018

15.1K

Related Concept Videos

Cancer Therapies02:49

Cancer Therapies

Cancer therapies are various modes of treatment, such as surgery, radiation therapy, and chemotherapy that are administered to cancer patients.
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
10.2K
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
9.0K
Treatment Resistant Cancers02:56

Treatment Resistant Cancers

Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
3.8K
Tumor Immunotherapy01:27

Tumor Immunotherapy

Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.
2.1K
Chronic Kidney Disease III: Interprofessional Care01:28

Chronic Kidney Disease III: Interprofessional Care

Chronic kidney disease (CKD) requires collaborative and comprehensive management. CKD progresses through stages and can lead to end-stage kidney disease (ESKD) if untreated. Interprofessional collaboration and patient education are crucial, enabling patients to manage their health and improve their quality of life.Diagnostic approach for chronic kidney diseaseThe diagnosis of CKD primarily focuses on the glomerular filtration rate (GFR), which assesses kidney function by measuring how well...
503
Combination Therapies and Personalized Medicine02:50

Combination Therapies and Personalized Medicine

Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
6.2K